Young Nicola R, Gatta Luke A, Wheeler Sarahn M, Federspiel Jerome J, Dotters-Katz Sarah K
School of Medicine, Duke University, Durham, North Carolina.
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina.
Am J Perinatol. 2025 Jan 9. doi: 10.1055/a-2502-7225.
A single-center randomized trial showed improved latency with use of indomethacin and cefazolin (I/C) during and following exam-indicated cerclage (EIC). The same center recently published a pre/post comparison demonstrating similar results. This research aimed to validate the protocol in a different setting.
Retrospective cohort study of singleton pregnancies undergoing EIC at a single center between 2013 and 2022. EIC was performed for painless cervical dilation between 16 and 23 weeks' gestation with dilation ≥1 cm. Exposure was defined as receipt of I/C during and following EIC. The primary outcome was latency ≥ 28 days after cerclage placement. Secondary outcomes included latency; gestational age at delivery; delivery ≤ 28 weeks; preterm premature rupture of membranes; intra-amniotic infection (IAI); and median birth weight. Bivariate statistics were used to analyze data; multivariable regression analyses were used to control for confounders (progesterone use, cervical dilation at time of cerclage placement, history of preterm birth, and prolapsing membranes).
EIC was placed in 81 pregnancies and 48 (59%) received I/C. Baseline characteristics did not differ between groups, except that prolapsing membranes were significantly less likely in patients receiving I/C (6.2 vs. 21.2%; = 0.04). Latency ≥ 28 days occurred in 90% of I/C recipients and 82% of the controls ( = 0.32); this difference remained nonsignificant after controlling for confounders (adjusted relative risk: 1.02 [95% confidence interval: 0.85, 1.21]). I/C recipients had lower rates of IAI (4.2 vs. 24.2%, = 0.007), even after adjustment (adjusted relative risk: 0.18 [95% confidence interval: 0.04, 0.74]). Other secondary outcomes did not differ.
Use of I/C at the time of EIC at this center was not associated with increased latency to delivery (albeit in a small cohort) but was associated with lower rates of intra-amniotic infection. Larger-scale validation studies would be helpful to confirm the value of this intervention.
· Indomethacin/cefazolin (I/C) increased latency for exam-indicated cerclage in a trial.. · We performed an observational comparison to validate these findings.. · I/C use for exam-indicated cerclages was associated with decreased intra-amniotic infection.. · I/C was not associated with change in latency.. · Larger-scale validation studies needed to confirm the value of intervention..
一项单中心随机试验表明,在检查指征性宫颈环扎术(EIC)期间及之后使用吲哚美辛和头孢唑林(I/C)可改善潜伏期。同一中心最近发表了一项前后对照研究,结果相似。本研究旨在在不同环境中验证该方案。
对2013年至2022年在单一中心接受EIC的单胎妊娠进行回顾性队列研究。EIC用于妊娠16至23周期间无痛宫颈扩张且扩张≥1厘米的情况。暴露定义为在EIC期间及之后接受I/C。主要结局是宫颈环扎术后潜伏期≥28天。次要结局包括潜伏期;分娩时的孕周;分娩孕周≤28周;早产胎膜早破;羊膜腔内感染(IAI);以及出生体重中位数。采用双变量统计分析数据;多变量回归分析用于控制混杂因素(使用孕激素、宫颈环扎时的宫颈扩张、早产史和胎膜脱垂)。
81例妊娠接受了EIC,其中48例(59%)接受了I/C。两组的基线特征无差异,但接受I/C的患者胎膜脱垂的可能性显著较低(6.2%对21.2%;P = 0.04)。90%的I/C接受者和82%的对照组出现潜伏期≥28天(P = 0.32);在控制混杂因素后,这种差异仍无统计学意义(调整后的相对风险:1.02 [95%置信区间:0.85,1.21])。即使经过调整,I/C接受者的IAI发生率也较低(4.2%对24.2%,P = 0.007)(调整后的相对风险:0.18 [95%置信区间:0.04,0.74])。其他次要结局无差异。
在该中心,EIC时使用I/C与分娩潜伏期增加无关(尽管队列较小),但与羊膜腔内感染率较低有关。更大规模的验证研究将有助于确认这种干预措施的价值。
· 在一项试验中,吲哚美辛/头孢唑林(I/C)增加了检查指征性宫颈环扎术的潜伏期。· 我们进行了一项观察性比较以验证这些发现。· I/C用于检查指征性宫颈环扎术与羊膜腔内感染减少有关。· I/C与潜伏期变化无关。· 需要更大规模的验证研究来确认干预措施的价值。